CEL-SCI advances Multikine study with FDA nod, eyes non-dilutive funding for commercial push

CEL-SCI Corporation has taken a significant step toward commercializing its investigational Multikine neoadjuvant therapy, as the U.S. Food and Drug Administration (FDA) review of its ... Read More